Mankind Pharma
Working at Mankind Pharma
Company Summary
Overall Rating

On-Par with

Highly rated for
Salary
Work Policy




Top Employees Benefits
About Mankind Pharma

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 17,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC, and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel, and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries, and CIS countries.
Mankind Pharma Ratings
Overall Rating
Category Ratings
Salary
Skill development
Company culture
Job security
Work-life balance
Work satisfaction
Promotions
Work Policy at Mankind Pharma
Mankind Pharma Reviews
Top mentions in Mankind Pharma Reviews
Compare Mankind Pharma with Similar Companies
Change Company | Change Company | Change Company | ||
---|---|---|---|---|
Overall Rating | 3.9/5 based on 2.5k reviews | 4.0/5 based on 5.8k reviews | 4.1/5 based on 6.9k reviews | 5.0/5 based on 1 reviews |
Highly Rated for | Salary | Salary Skill development Job security | Skill development Salary Work-life balance | Skill development Work-life balance Salary |
Critically Rated for | No critically rated category | No critically rated category | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 71% employees reported | Work from office 82% employees reported | Work from office 73% employees reported | - |
Rating by Women Employees | 3.7 Good rated by 131 women | 4.0 Good rated by 441 women | 4.1 Good rated by 680 women | - no rating available |
Rating by Men Employees | 3.9 Good rated by 2.2k men | 4.0 Good rated by 5k men | 4.1 Good rated by 5.8k men | - no rating available |
Job security | 3.6 Good | 3.8 Good | 3.7 Good | 4.0 Good |
Mankind Pharma Salaries
Officer
Research Associate
Research Scientist
Senior Officer
Medical Representative
Area Sales Manager
Deputy Manager
Senior Research Scientist
Regional Sales Manager
Area Manager
Mankind Pharma Interview Questions
Interview questions by designation
Top Mankind Pharma interview questions and answers
Mankind Pharma Jobs
Mankind Pharma News
Share Market Highlights 25 February 2025: Sensex, Nifty end flat with a positive bias; Bharti Airtel, M&M lead gains
- Zaggle, a Hyderabad-based software-as-a-service company, will provide comprehensive services for the citizen card and implement the Visitor Management System in GIFT City.
- GIFTCL and Zaggle have entered into a five-year agreement with possible extensions to enhance security and streamline access within GIFT City.
- Axis Finance is undergoing a strategic review with a potential valuation of $900 million to $1 billion, as disclosed by unidentified sources.
- Companies like Max Healthcare, Mankind, and Ashok Leyland witnessed stock gains, whereas Petronet LNG and Delhivery faced losses.
- Tata Capital, with an AUM of ₹1,58,479 crore as of March 2024, is issuing shares worth ₹1,504 crore on a rights basis, with an IPO size expected to be around ₹15,000 crore.
- Camlin Fine Sciences acquires a majority stake in French natural ingredients company Vinpai S.A. to enhance its product range and capabilities.
- Dodo Payments secures $1.1 million in a pre-seed funding round led by Antler, 9Unicorns, and Venture Catalysts, aimed at simplifying international payments for businesses.
- AI adoption in energy companies for predictive maintenance and personalized customer engagement is growing, with GenAI playing a crucial role in enhancing core operations.
- A new environmentally friendly 3-wheeled vehicle, MOBILI SWAP, aims to reduce operating costs and improve efficiency in the transport sector with interchangeable batteries.
- Former President Ranjan Bargotra re-joins Crayons Advertising as Executive Director, bringing strategic expansion plans and extensive industry experience.

Pet Food Brand Dogsee Chew Raises $8 Mn To Scale Global Operations
- Bengaluru-based pet food brand Dogsee Chew has raised $8 million in a Series B funding round led by Ektha.com, with participation from Shivanssh Holdings and Poddar Family office.
- The funding will be used to expand manufacturing capabilities and establish a stronger presence in international markets, particularly the US and Canada.
- Dogsee Chew is known for its vegetarian treats made from Himalayan cheese and aims to become the largest Himalayan chew manufacturer globally.
- The company has already secured previous investments from Mankind Pharma, Sixth Sense Ventures, and has a strong global presence in over 30 countries.

MSCI Rejig: Hyundai India Only Addition In February Review; IndusInd Bank, Zomato Weights To Rise
- Hyundai Motor India, IndusInd Bank, Zomato, Varun Beverages, and Mankind Pharma will have increased weightage in the February MSCI review.
- India's weight in MSCI Global Standard Indexes will rise to 19% from the current 18.8% after the quarterly rejig.
- HDFC Bank holds the highest weightage among Indian stocks in MSCI indexes, followed by Reliance Industries, ICICI Bank, Infosys, and Bharti Airtel.
- MSCI added 19 Indian small-cap stocks and removed an equal number from its indices.

Mankind Pharma Approves Sale Of Entire Stake In Wholly Owned Mahananda Spa And Resorts To Chalet Hotels
- Mankind Pharma has approved the sale of its entire stake in Mahananda Spa and Resorts.
- The sale is to Chalet Hotels for an enterprise value of Rs 530 crore.
- The proceeds will be used to retire part of Mankind Pharma's debts.
- The transaction is expected to be completed by February 28.

Tech Query: What is the outlook for Infosys, Barbeque-Nation Hospitality, Mankind Pharma, Happiest Minds Technologies?
- Infosys: The stock is in an uptrend and has been consolidating between ₹1,700 and ₹2,000. Strong support is at ₹1,800-₹1,700. If above support, the outlook remains bullish and a break above ₹2,000 could take the stock to ₹2,300-₹2,400.
- Barbeque-Nation Hospitality: The stock is in a downtrend and has fallen significantly. Resistance is at ₹385 and there is a risk of the stock declining to ₹120. Accumulating at current levels is not advisable. Exit and accept the loss.
- Mankind Pharma: The stock is in a corrective fall and can touch ₹2,250, after which a rally could take it to ₹3,200 over the next couple of years. Selling 20% of the holding and buying at ₹2,300 with a stop-loss at ₹2,140 is recommended.
- Happiest Minds Technologies: The stock is in a downtrend and could fall to ₹610-₹600. Holding on to the stock is not advisable. Consider reinvesting in another stock, such as Mankind Pharma.

Buy, Sell Or Hold: Zomato, RVNL, IRFC, Mankind Pharma, IOC, Bajaj Housing Finance — Ask Profit
- Analysts shared insights on share prices of Zen Technologies, Mankind Pharma, and Natco Pharma.
- RVNL (CMP: Rs 427.65) was advised to hold with strong support at Rs 410–415 levels.
- IRFC (CMP: Rs 141.73) was recommended to hold for one to two weeks with an upside target of 5–8% and a potential to reach Rs 155.
- Mankind Pharma (CMP: Rs 2,477.5) was suggested as a buy with a long-term target of Rs 2,700 in one year.
- Bajaj Housing Finance (CMP: Rs 1,115.87) was advised as a buy, as the numbers were good and there is a good upside potential.
- Zomato (CMP: Rs 222.50) was recommended as a sell, given the high volatility and overall downward trend in the stock.
- Natco Pharma (CMP: Rs 1,171.00) was advised to hold with a target of Rs 1,450 in six-eight months.
- Indian Oil Corp (CMP: Rs 123.64) was suggested to hold with a target of Rs 150–160 in six to 12 months.
- Zen Technologies (CMP: Rs 1,695.30) was recommended to hold for one to two years as a good pick in the long term.
.jpg?w=1200&auto=format%2Ccompress&ogImage=true)
Mankind Pharma, Innovent Biologics Partner To Launch Sintilimab In India
- Mankind Pharma and Innovent Biologics have partnered to launch the immunotherapy drug Sintilimab in the Indian market.
- The collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region.
- Sintilimab is co-developed by Innovent and Eli Lilly and is marketed as TYVYT in China.
- Mankind Pharma will file for regulatory approval in India and conduct a phase 3 clinical trial to obtain approval for Sintilimab in the country.

Mankind Pharma, Innovent Biologics partner to bring immunotherapy drug sintilimab to India
- Mankind Pharma has partnered with Innovent Biologics to bring immunotherapy drug sintilimab to India.
- Sintilimab, marketed as Tyvyt, is a monoclonal antibody that blocks the PD-1/PD-L1 pathway, reactivating T-cells to target and eliminate cancer cells.
- The drug has shown efficacy and safety across multiple cancer types and is already approved for eight indications in China.
- Mankind Pharma will have exclusive rights to market and distribute sintilimab in India, while Innovent will oversee manufacturing and supply.
Today Startup News 17 December 2024 From The Indian Startup Ecosystem
- Mili, an AI meeting assistant for wealth management platform, secures $2 million in seed funding led by Chiratae and BoldCap.
- Crown Veterinary Services (Crown Vet), a healthtech startup, raises undisclosed funds from Mars Veterinary Health.
- Mankind Pharma launches Rs 3,000 crore QIP to fund Bharat Serums acquisition.
- The Competition Commission of India (CCI) approves KKR's stake acquisition in Rebel Foods.

Mankind Pharma Launches Rs 3,000 Cr QIP To Fund Bharat Serums Acquisition
- Mankind Pharma has launched a QIP to raise up to Rs 3,000 crore for the acquisition of Bharat Serums and Vaccines (BSV).
- Kotak Mahindra Capital and IIFL Capital are serving as advisors for the QIP.
- The acquisition of BSV will make Mankind Pharma a leader in the Indian women's health and fertility drug market.
- Mankind Pharma reported a 29% increase in net profit for Q2 2024.

Mankind Pharma Subsidiaries
Pathkind Diagnostics Private Limited
Mankind Pharma Offices
Compare Mankind Pharma with




















Contribute & help others!
Companies Similar to Mankind Pharma












Mankind Pharma FAQs
Reviews
Interviews
Salaries
Users/Month